Adicet Bio, Inc. (ACET)

Market Cap	74.85M
Revenue (ttm)	n/a
Net Income (ttm)	-117.88M
Shares Out	82.40M
EPS (ttm)	-1.55
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	203,246
Open	0.910
Previous Close	0.920
Day's Range	0.880 - 0.927
52-Week Range	0.810 - 3.620
Beta	1.65
Analysts	Strong Buy
Price Target	5.67 (+524.17%)
Earnings Date	Nov 6, 2024

About ACET

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. The company offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. Its lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Th...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1947
• Employees: 143
• Stock Exchange: NASDAQ
• Ticker Symbol: ACET
• Website: https://www.adicetbio.com

Analyst Forecast

According to 4 analysts, the average rating for ACET stock is "Strong Buy." The 12-month stock price forecast is $5.67, which is an increase of 524.17% from the latest price.

Price Target

$5.67

(524.17% upside)

Analyst Consensus: Strong Buy